stockrow
Friday 6 November 2026
Export CLRB’s income statement to Excel — free account
Cellectar Biosciences, Inc.
CLRB Healthcare Biotechnology
- EPS
- +83.2%
- Free cash flow
- −17.5%
Quarter to June 2026, against a year earlier
1.24
0.09
+7.83%
Follow CLRB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (125.99%) | (395.20%) | (200.01%) | (417.71%) |
+8 more TTM periods Free account |
|
| (88.70%) | (153.46%) | (107.74%) | (72.62%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(74.55%) | (440.33%) | (221.49%) | (202.60%) | |
Free Cash Flow per Share |
(1.60) | (4.40) | (8.90) | (9.39) | |
Free Cash Flow |
(19.55) | (18.65) | (23.21) | (29.69) | |
Capital Expenditures |
(0.07) | (0.07) | (0.09) | — | |
| Other line items | |||||
Cash ROIC |
(30.60%) | (159.65%) | (106.78%) | (142.13%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.87 | 0.89 | 1.06 | 1.57 | |
Depreciation/Fixed assets |
0.09 | 0.14 | 0.39 | 0.39 | |
Capex/Depreciation |
(2.60) | (1.49) | (0.41) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.59) | (4.38) | (8.86) | (9.39) | |
Capex per Share |
(0.01) | (0.02) | (0.03) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026